All In Biotech

Drug Trial Radar · NCT03825744

Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia

A Phase III Multicenter Randomized Study of Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia

Last checked: Nov 19, 2026Latest source record: Nov 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

240

Actual

Start

Mar 5, 2019

Primary completion

Jul 3, 2024

Study completion Jul 3, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 31, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 15 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, placebo-control, phase III study to investigate hetrombopag in subjects with severe AA who are treated naive. 180 treated naive patients with SAA will be enrolled in the study. The primary objective of the study will be the rate of complete hematologic response at six months.

Conditions

  • Severe Aplastic Anemia

Interventions

  • Hetrombopag Olamine+Standard TherapyDrug

    once daily

  • Placebo+Standard TherapyDrug

    once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of complete hematologic response at six months.Time frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.